- PMID: 37146933
- DOI: 10.1016/j.envres.2023.115862
Abstract
Cancer is a major global public health concern that affects both industrialized and developing nations. Current cancer chemotherapeutic options are limited by side effects, but plant-derived alternatives and their derivatives offer the possibilities of enhanced treatment response and reduced side effects. A plethora of recently published articles have focused on treatments based on cannabinoids and cannabinoid analogs and reported that they positively affect healthy cell growth and reverse cancer-related abnormalities by targeting aberrant tumor microenvironments (TMEs), lowering tumorigenesis, preventing metastasis, and/or boosting the effectiveness of chemotherapy and radiotherapy. Furthermore, TME modulating systems are receiving much interest in the cancer immunotherapy field because it has been shown that TMEs have significant impacts on tumor progression, angiogenesis, invasion, migration, epithelial to mesenchymal transition, metastasis and development of drug resistance. Here, we have reviewed the effective role of cannabinoids, their analogs and cannabinoid nano formulations on the cellular components of TME (endothelial cells, pericytes, fibroblast and immune cells) and how efficiently it retards the progression of carcinogenesis is discussed. The article summarizes the existing research on the molecular mechanisms of cannabinoids regulation of the TME and finally highlights the human studies on cannabinoids’ active interventional clinical trials. The conclusion outlines the need for future research involving clinical trials of cannabinoids to demonstrate their efficacy and activity as a treatment/prevention for various types of human malignancies.
Keywords: Cancer, Cannabinoids, Cannabis, Clinical trials, Tumor microenvironment
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.Curr Cancer Drug Targets. 2013 Jun;13(5):486-99. doi: 10.2174/15680096113139990041.PMID: 23617249 Free PMC article. Review.
-
The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes.Pharmaceut Med. 2022 Dec;36(6):387-400. doi: 10.1007/s40290-022-00447-7. Epub 2022 Nov 10.PMID: 36357543
-
Cannabinoids as Anticancer Drugs.Adv Pharmacol. 2017;80:397-436. doi: 10.1016/bs.apha.2017.04.002. Epub 2017 Jun 12.PMID: 28826542 Review.
-
Therapeutic potential of cannabinoids in combination cancer therapy.Adv Biol Regul. 2021 Jan;79:100774. doi: 10.1016/j.jbior.2020.100774. Epub 2021 Jan 6.PMID: 33422460 Review.
-
Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.Epilepsy Behav. 2017 May;70(Pt B):319-327. doi: 10.1016/j.yebeh.2016.11.006. Epub 2017 Feb 9.PMID: 28190698 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut – more resources
-
Full Text Sources
-
Medical